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Marrow and Peripheral Blood Progenitor Cell Grafts on
Transplantation Outcomes
Nancy H. Collins,1 Adrian P. Gee,2 April G. Durett,2 Fangyu Kan,3 Mei-Jie Zhang,4
Richard E. Champlin,5 Dennis Confer,3 Mary Eapen,4 Alan Howard,3 Roberta King,3
Mary J. Laughlin,6 Robert J. Plante,3 Michelle Setterholm,3 Stephen Spellman,3
Carolyn Keever-Taylor,7 John E. Wagner,8 Daniel J. Weisdorf 8To test the hypothesis that the outcome of hematopoietic stem cell (HSC) grafts is at least partially deter-
mined by the cellular composition of the graft, the National Marrow Donor Program (NMDP) analyzed
the correlation of cellular phenotypes of unrelated grafts with graft outcome. Samples from 94 bone marrow
(BM) and 181 peripheral blood progenitor cell (PBPC) grafts for transplantations at 40 U.S. transplant centers
between 2003 and 2005 were analyzed at a single immunophenotyping reference laboratory. Samples were
shipped from transplant centers upon receipt of graft. Graft cellular composition included analysis of leuko-
cyte total cell numbers, and subsets of myeloid [CD341, CD341 CD382], lymphoid [CD31, CD31 CD41,
CD31CD81], and activated lymphoid cells [CD31CD251, CD31CD691, CD31HLA-DR1] coexpressing
CD31. There was substantial variability in the cellular composition of BM and PBPC grafts before and after
graft processing by red blood cell (RBC) removal or plasma depletion in preparation for transplant. With BM
grafts, cellular composition was not associated with hematopoietic recovery, graft-versus-host disease
(GVHD), or survival. With PBPC grafts, survival rates were higher with CD341. 5 106/kg, 59% com-
pared to 34% with CD341# 5 106/kg at 1 year. Platelet recovery was higher with PBPC containing
CD31 CD81 .8 107/kg. Neutrophil recovery or GVHD could not be predicted by any cellular subsets
of PBPC grafts. Although survival was superior with PBPC grafts containing.5 106 CD341/kg, an optimal
graft mix of myeloid, lymphoid, and activated lymphoid subsets was not identified.
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6/j.bbmt.2009.10.004disease, and graft factors. Although donor-recipient
HLA matching is the major determinant of trans-
plant-outcome after unrelated donor transplantation,
among graft factors, product cellular composition, cell
dose, and the effects of postharvest, preinfusion pro-
cessing are considered sufficiently important to influ-
ence transplant outcome. However, after almost 3
decades of allogeneic HCT using volunteer unrelated
bone marrow (BM) or peripheral blood progenitor cells
(PBPC), the optimal cellular composition of these grafts
has not been defined. Prior trials using diverse patient
populations have reported conflicting results in corre-
lating the composition of BM and PBPC grafts [1-8]
with transplant outcome. Therefore, this study was de-
signed to examine the composition of volunteer unre-
lated donor grafts and the effect on graft outcomes.
The various methods of graft processingmay affect
the cellular composition of the final product. Themost
common graft manipulations are red blood cell (RBC)
removal, plasma depletion, and mononuclear cell con-
centration. The aim of these simplemanipulations is to253
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plasma antibodies (isohemagglutinins) from the graft
without significant loss of hematopoietic progenitor
cells or lymphocyte subsets. In contrast, the more
complex procedures of T cell depletion or CD341
cell selection profoundly affect graft composition
with the specific aim of modifying numbers of certain
cell types to improve engraftment or decrease graft-
versus-host disease (GVHD) [6,7]. Flow cytometric
analysis of the graft may provide a rapid predictive
measure of graft outcome [2-5,7,8]. However, interla-
boratory standardization in analyzing grafts is difficult,
as gating and subset enumeration still remains an art
rather than a precise science, particularly for complex
cellular samples such as BM or mobilized PBPC.
The use of a single reference laboratory offers the ad-
vantages of consistency and efficiency, but the logistics
and costs of sample collection and shipment to the ref-
erence laboratory can limit the feasibility of standard-
ized data collection. Furthermore, the quality of the
data obtained may be compromised by the effects of
transport time and temperature on overall sample in-
tegrity and cellular viability [9].MATERIALS AND METHODS
Study Population: Patient, Disease, and
Transplant Characteristics
This study was developed to prospectively deter-
mine the relationship between graft myeloid and lym-
phoid subset cell dose and clinical outcome for BM and
PBPC grafts, using data from a single immunopheno-
typing reference laboratory. The study was developed
and coordinated by the National Marrow Donor Pro-
gram (NMDP, Minneapolis, MN), following approval
of the protocol from the NMDP Institutional Review
Board. Forty-five participating transplant centers were
recruited through the NMDP; however, only 40 trans-
plant centers provided patient consent, samples, and
complete phenotypic and clinical data (see list of par-
ticipating transplant centers, Appendix 1). Conse-
quently, the study population (94 BM and 181 PBPC
recipients) were transplanted at 40 centers in the
United States between July 2003 and March 2005. Re-
cipients of T cell-depleted (BM; n5 29) and CD341
selected (PBPC; n5 17) transplants from these centers
were excluded, as most centers did not send a sample to
the reference laboratory postprocessing.
All grafts were characterized for cellular quantity
and quality and studied to determine the effects of lab-
oratory processing on graft composition. Specifically,
we examined the impact of graft composition mea-
sured by total white blood cell (WBC) numbers, and
the number of cells belonging to the myeloid subset
[CD341, CD341 CD382], the lymphoid subset
[CD31, CD31 CD41, CD31 CD81], and activatedlymphoid cells [CD31 CD251, CD31 CD691,
CD31 HLA-DR1] coexpressing CD31. Constraints
of cell numbers dictated that other subpopulations of
lymphocytes, notably regulatory T cells (Tregs),
were not analyzed. The outcome parameters of hema-
tologic recovery, acute and chronic GVHD (aGVHD,
cGVHD), and survival were analyzed, with a median
follow-up of 2 years. Data were adjusted for patient,
disease, and transplant characteristics.
Definition of Outcomes
The primary outcome of this analysis was overall
survival (OS) defined as time from infusion of graft
to death from any cause. Surviving patients were cen-
sored at last follow-up. Secondary endpoints evaluated
include: (1) neutrophil recovery defined as achieving
neutrophil count $0.5 109/L for 3 consecutive
measurements, (2) platelet recovery to $20 109/L
for 7 days, unsupported, (3) grade II-IV aGVHD
as defined by the Glucksberg scale [10], and (4)
cGVHD [11].
Sample Collection and Analysis
Unrelated donor BM or filgrastim-mobilized
PBPC grafts were couriered by standard NMDP ship-
ment protocols from the collection center to the trans-
plant center’s processing laboratory. Upon arrival at the
transplant center processing laboratory, a sample of the
original productwas shipped to the reference laboratory
(sample 1). If the graft underwent further processing
(RBC or plasma depletion) at the transplant center,
the processing laboratory sent a sample of the graft after
processing (sample 2). Both samples were packaged and
shipped (in insulated cool packs) to the central reference
laboratory, Baylor College of Medicine Center for Cell
andGeneTherapy (CAGT). The samples were shipped
inside secondary containers with frozen gel packs in
Class 6.2 shipping containers and transported by over-
night delivery service to the reference laboratory.
The transplant center processing laboratory re-
ported data on type of processing (no processing,
mononuclear cell concentration, plasma depletion,
red blood cell removal), time of collection, and time
of processing. Upon receipt of the samples, the refer-
ence laboratory recorded the condition of the sample,
the packaging condition (orientation, temperature and
number of gel packs), and the time from collection and
processing. Each sample was assessed for overall sam-
ple integrity and filtered using a 40-mm Cell Strainer
(Falcon #352340, Lincoln Park, NJ), if cellular aggre-
gates were present. Only samples that were free of vis-
ible clumps and were at least 70% viable (by 7 AAD
staining) were included in the analysis. Leukocyte
count of the sample was enumerated using a Coulter
AcT 8/10 Analyzer (Beckman-Coulter, Miami, FL).
In preparation for immunophenotyping each sample
Biol Blood Marrow Transplant 16:253-262, 2010 255Graft Composition and Transplant Outcomewas adjusted to 1 107 cells per mL. Saturation con-
centrations of conjugated monoclonal antibodies
(mAbs) (BDIS: CD45, CD341, CD381, CD31,
CD31 CD41, CD31 CD81, CD31 CD691, CD31
CD251, and CD31 HLA-DR1) were added to
12 75 mm polystyrene tubes (Falcon 352008), fol-
lowed by 100 mL (106) cells and incubated 15 min at
ambient temperature (18-22 C) in the dark. The anti-
bodies and reagents are ASR reagents purchased from
Becton-Dickinson Biosciences (Franklin Lakes, NJ)
and include CD45 clone 2D1, CD34 class III clone
8G12, CD3 clone SK7, CD4 clone SK3, CD8 clone
SK1, CD69 clone L78, CD25 clone 2A3, and HLA-
DR clone L243. Also included, but not requested in
the study design, CD19 clone 4G7 and CD16 clone
B73.11CD56 clone MY31, to serve as internal Lym-
pho-Sum control. All antibodies were used at saturated
concentrations against the antigen concentration and
determined by in-house checkerboard titration and/
or used at the manufacturers suggested concentration.
Commercial reference controls (CD-Chex Plus from
Streck Laboratories, Inc., Omaha, NE) were run
each day of sample evaluation as quality control of
the staining acquisition and analysis for CD34, CD3,
CD4, CD8, and HLA markers, in addition to the
B-cell and NK-cell markers. There were no commer-
cial controls available for the activation markers CD69
and CD25. Additionally, a combination of CD45 and
CD14 was included to provide a 3-part differential
that was also used as an internal control to ensure
that the sum ofT1 B1NKcells was equal to the lym-
phocytes. The samples were processed using a pro-
grammable Lyse-Wash Assistant (BDIS), lysing the
erythrocytes with ammonium chloride-based solution
(PharM Lyse, BDIS). Viability after phenotyping was
assessed using 7AAD (ViaProbe, BDIS). Data were ac-
quired using single laser (488 nm) flow cytometer with
Cell-Quest Pro software. For progenitor cells, a total
of 100,000 events were stored in list mode; and 20,000
total events for lymphocyte and viability data. The ac-
quisition software was also used for the analysis of the
list mode data. The CD341 enumeration was per-
formed using ISHAGE gating strategy [12]. The lym-
phocytes were enumerated by defining a light scatter
region around the lymphocyte population. The region
was confirmed by CD3 backgating and the subsets co-
expressing CD3 were enumerated (CD31 CD41,
CD31 CD81, CD31 CD691, CD31 CD251, and
CD31 HLA-DR1).Statistical Analysis
Median value and ranges are reported for continu-
ous variables and percentages for categoric variables.
The probability of OS was calculated using the
Kaplan-Meier estimator [13]. The probabilities of neu-
trophil and platelet recovery and aGVHD and cGVHDwere calculated with the cumulative-incidence estima-
tor [14]. Death was considered a competing risk for he-
matopoietic recovery and GVHD. Patients were
censored if they underwent a second transplant, or at
last follow-up. Ninety-five percent confidence intervals
(CI) were calculated with log transformation.
To analyze the association of cellular composition
(white blood cell count, CD341, CD341 CD382,
CD31, CD31 CD41, CD31 CD81, CD31 CD251,
CD31CD691, andCD31HLA-DR1) and clinical out-
comes, multivariate logistic regression models were con-
structed for each cellular component for hematopoietic
recovery, and Cox proportional hazards regression
models [15] were constructed for aGVHDand cGVHD,
andOS. All the cell dose effects were analyzed as a binary
variable. To dichotomize the continuous variables, Mar-
tingale residuals were plotted for each cell dose to deter-
mine the optimal cut point. We concluded that the
medians were good cutoff points for all cell doses and
thus a binary variable with median as cut point was
used for all subsets analyzed. Other variables tested in-
cluded age, performance score, disease (malignant versus
nonmalignant), disease status at transplantation (early
versus intermediate versus advanced disease vesus non-
malignant disease), conditioning regimen (myeloablative
[MA] versus reduced-intensity conditioning [RIC] versus
conditioning for nonmalignant diseases), donor-recipi-
ent HLA match (well-matched versus partially matched
versus mismatched) [16], donor-recipient cytomegalovi-
rus (CMV) serostatus, ABO mismatch, donor age, and
graft processing (mononuclear cell concentration versus
plasma depletion versus red blood cell removal versus
none). Because of the multiple comparisons included in
the statistical analysis, a P\ .01 was defined as statisti-
cally significant. All P-values were 2 sided. All analyses
were performed using SAS 9.1 (SAS Institute, Cary,
NC).RESULTS
The demographic, disease, and transplant charac-
teristics of the 94 BM and 181 PBPC recipients are
outlined on Table 1. The median age was 20 years
(range:\1-66) for BM recipients and 45 years (\1-
70) for PBPC recipients. Most patients had high-per-
formance scores; performance scores were $90 for
81% of BM and 71% of PBPC recipients. Nearly all
transplants (85% BM and 94% PBPC) were for treat-
ment of malignancy. Transplant conditioning regi-
mens for hematologic malignancies included both
MA (70% of BM and 54% of PBPC transplants) and
RIC regimens (15% of BM and 40% of PBPC trans-
plants). Only 14 (15%) BM and 10 (6%) PBPC trans-
plants were for nonmalignant diseases. Donor and
recipient were HLA well-matched for 73% of BM
and 66% of PBPC transplants.
Table 1. Patient, Disease, and Transplant Characteristics
Bone marrow (BM) Peripheral Blood Progenitor Cells (PBPCs)
Variables Number (%) Number (%)
Number of cases 94 181
Sex, male 52 (55) 111 (61)
Age, in years, median (range) 20 (<1-66) 45 (<1-70)
10 or under 10 22 (23) 13 (7)
11-20 22 (23) 16 (9)
21-30 6 (6) 23 (13)
31-40 14 (15) 22 (12)
41-50 13 (14) 41 (23)
51-60 13 (14) 44 (24)
> 60 4 (4) 22 (12)
Karnofsky performance score 90-100 65 (81) 118 (71)
Diseases
Acute myelogenous leukemia 29 (31) 62 (34)
Acute lymphoblastic leukemia 15 (16) 39 (22)
Other leukemia 4 (4) 15 (8)
Chronic myelogenous leukemia 13 (14) 13 (7)
Myelodysplastic syndrome 10 (11) 24 (13)
Non-Hodgkin lymphoma 8 (9) 16 (9)
Plasma cell disorder, multiple myeloma 2 (2) 3 (2)
Other malignancy 0 2 (1)
Severe aplastic anemia 7 (7) 5 (3)
SCID and other immune system disorders 1 (1) 0
Inherited disorder of metabolism 2 (2) 1 (1)
Histiocytic disorders 3 (3) 1 (1)
Disease status prior to transplant*
Early 22 (23) 45 (25)
Intermediate 24 (26) 42 (23)
Advanced 34 (36) 84 (46)
Nonmalignant 14 (15) 10 (6)
Conditioning regimen
Malignant diseases, myeloablative 66 (70) 98 (54)
Malignant diseases, reduced intensity 14 (15) 73 (40)
Nonmalignant diseases, other 14 (15) 10 (6)
HLA disparity†
Well-matched 69 (73) 119 (66)
Partially matched 20 (21) 41 (23)
Mismatched 5 (5) 21 (12)
Cytomegalovirus serostatus
Donor negative/recipient negative 27 (29) 52 (29)
Donor negative/recipient positive 35 (37) 63 (35)
Donor positive/recipient negative 11 (12) 25 (14)
Donor positive/recipient positive 20 (21) 38 (21)
Unknown 1 (1) 3 (2)
ABO match
Matched 45 (48) 67 (37)
Minor mismatch 15 (16) 55 (30)
Major mismatch 28 (30) 41 (23)
Bidirectional 5 (5) 18 (10)
Unknown 1 (1) 0
Donor-recipient sex match
Male donor—male recipient 31 (33) 85 (47)
Male donor—female recipient 34 (36) 42 (23)
Female donor—male recipient 21 (22) 26 (14)
Female donor—female recipient 8 (9) 28 (15)
Donor age, years
18-30 27 (29) 56 (31)
31-40 37 (39) 68 (38)
41-50 25 (27) 46 (25)
51-60 5 (5) 11 (6)
Year of transplant
2003 22 (23) 46 (25)
2004 56 (60) 100 (55)
2005 16 (17) 35 (19)
Graft processing type
Mononuclear cell concentration 6 (6) 0
Plasma depletion 15 (16) 37 (20)
Red blood cell removal 32 (34) 1 (1)
None 41 (44) 143 (79)
(Continued )
256 Biol Blood Marrow Transplant 16:253-262, 2010N. H. Collins et al.
Table 1. (Continued )
Bone marrow (BM) Peripheral Blood Progenitor Cells (PBPCs)
Variables Number (%) Number (%)
Median follow-up survival, months (range) 24 (6-30) 24 (3-37)
Cell dose per kg, median (range)
WBC 2.34 108 (4.33 106-9.56 108) 7.23 108 (4.06 107-4.69 109)
CD34+ 3.62 106 (1.02 105-1.84 107) 5.41 106 (3.08 105-3.23 107)
CD34+ CD382 9.44 104 (8.76 102-7.39 105) 1.54 105 (8.12 103-1.07 106)
CD3+ 2.54 107 (6.43 105-1.21 108) 2.37 108 (2.19 107-2.05 109)
CD3+ CD4+ 1.33 107 (2.87 105-6.06 107) 1.45 108 (1.43 107-1.29 109)
CD3+ CD8+ 1.09 107 (2.94 105-7.52 107) 8.37 107 (7.07 106-6.69 108)
CD3+ CD25+ 3.05 106 (1.08 105-1.72 107) 2.46 107 (2.34 106-2.40 108)
CD3+ CD69+ 3.38 106 (1.43 105-2.64 107) 3.55 106 (1.51 105-3.89 107)
CD3+ HLA-DR+ 3.92 106 (8.59 104-3.50 107) 2.18 107 (1.62 106-2.06 108)
BM indicates bone marrow; SCID, severe combined immunodeficiency; CR, complete remission.
*Early is defined as CR1, CP1, RA, and RARS; intermediate is defined as$CR2+. AP, and$CP2; and advanced is defined as PIF, BP, relapse, RAEB, RAEBT,
CMMoL, Durie-Salmon Stage III, and Waldenstrom macroglobulinemia.
†Well-matched includes: 8/8 allele-level matched (BM n5 46, PBPC n5 91); allele-level matched A, B, DRB1, and low res matched at HLA-C (BM n5 7,
PBPC n5 8); low res matched at A, B, and C and allele-level DRB1 (BM n5 16, PBPC n5 19), allele-level matched at A, B, DRB1, and HLA-C unknown
(PBPC n5 1).
Partially matched includes: single locus antigen or allele-level MM at A, B, C, or DRB1(BM n5 19, PBPC n5 39); matched at low-res A, B, and high-res
DRB1 and HLA-C unknown (BM n5 1, PBPC n5 1); matched at low-res A, B, C, and DRB1 (PBPC n5 1).
Mismatched includes: >1 allele or antigen MM at A, B, C, DRB1 (BM5 4, PBPC n5 20); 1 antigenmismatch at high-res A, B, DRB1, and HLA-C unknown
(BM n51); 1 mismatch at low-res A, B, high-res at DRB1 and HLA-C unknown (PBPC n5 1).
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Figure 1. Effect of processing on BM product graft composition. (A)
Plasma depletion. (B) RBC removal.
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of Processing
Samples were assessed for temperature of gel
packs, sample integrity (absence of visible clumps after
gentle agitation or clots requiring filtration), viability
(.70%), and immunophenotype (CD341, CD31,
and CD31 T cell subsets, CD31 CD251, CD31
CD691, CD31 HLA-DR1). Samples from BM and
PBPC products included herein met sample integrity
and viability requirements. Compared to BM grafts,
PBPC grafts contained more nucleated cells
(7.23 108/kg versus 2.34 108/kg), CD31 cells
(2.37 108/kg versus 2.54 107/kg), and CD341
cells (5.41 106/kg versus 3.62 106/kg). Data on dif-
ferences in cellular composition before and after pro-
cessing (BM or PBPC) and type of processing are
shown in Figures 1 and 2. Fifteen BM grafts were sub-
ject to plasma depletion and 32 to RBC removal.
Plasma depletion of BM was not associated with
changes in CD341 and CD341 CD382, CD31, and
CD31 HLA-DR1 recovery (Figure 1A). In contrast,
RBC removal of BM grafts resulted in lower CD341,
CD341 CD382, and CD31 doses (Figure 1B).
Thirty-seven PBPC grafts were subject to plasma
depletion. CD31 dose was lower, but there were no dif-
ferences in CD341, CD341 CD382, or CD31 HLA-
DR1 doses before and after plasmadepletion (Figure 2).
Effect of Graft Composition on Post-HCT
Outcomes
Hematopoietic recovery
Ninety-two of 94 (98%) recipients of BM grafts
and 171 of 181 (94%) recipients of PBPC graftsachieved neutrophil recovery. The median time to
neutrophil recovery was 18 days and 13 days after
transplantation of BM and PBPC grafts, respectively.
Corresponding day 28 probabilities of neutrophil re-
covery were 94% (95% CI 87%-98%) and 93%
(95% CI 88%-96%). In multivariate analysis, neutro-
phil recovery after BM or PBPC transplantation was
not associated with white blood cell count, myeloid,
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Figure 2. Effect of processing on PBPC product graft composition–
plasma depletion. Numbers given on the figures were minimum, median,
and maximum of percentage recovery, and P-value from Kruskal-Wallis
test to compare cell doses between before and after processing.
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(Table 2). Sixty-nine of 94 (73%) recipients of BM
grafts and 149 of 181 (82%) recipients of PBPC grafts
achieved platelet recovery. Themedian time to plateletTable 2. Multivariate Analysis of Hematopoietic Recovery
Bone Marrow Neutrophil Recovery OR (95%
WBC
>2.34 versus #2.34, 108/kg 5.48 (0.61-48.80), 0.1
CD34+
>3.62 versus #3.62, 106/kg 1.00 (0.19-5.23), 1.00
CD34+ CD38-
>9.44 versus #9.44, 104/kg 2.09 (0.36-0.41), 0.41
CD3+
>2.54 versus #2.54, 107/kg 1.00 (0.19-5.23), 1.00
CD3+ CD4+
>1.33 versus #1.33, 107/kg 1.03 (0.14-7.66), 0.98
CD3+ CD8+
>1.09 versus #1.09, 107/kg 0.32 (0.03-3.18), 0.33
CD3+ CD25+
>3.05 versus #3.05, 106/kg 1.50 (0.24-9.50), 0.67
CD3+ CD69+
>3.38 versus #3.38, 106/kg 0.65 (0.10-4.11), 0.65
CD3+ HLA-DR+
>3.92 versus #3.92, 106/kg 0.48 (0.08-2.75), 0.41
Peripheral blood progenitor cells Neutrophil Recovery OR (9
WBC
>7.23 versus #7.23, 108/kg 1.17 (0.38-3.62), 0
CD34+
> 5.41 versus #5.41, 106/kg 1.17 (0.38-3.62), 0
CD34+ CD382
>1.54 versus #1.54, 105/kg 0.61 (0.19-1.94), 0
CD3+
>2.37 versus #2.37, 108/kg 1.64 (0.52-5.21), 0
CD3+ CD4+
>1.45 versus #1.45, 108/kg 0.60 (0.19-1.90), 0
CD3+ CD8+
>8.37 versus #8.37, 107/kg 2.36 (0.70-7.96), 0
CD3+ CD25+
>2.46 versus #2.46, 107/kg 6.13 (1.32-28.49),
CD3+ CD69+
>3.55 versus #3.55, 106/kg 3.62 (0.96-13.64),
CD3+ HLA-DR+
>2.18 versus #2.18, 107/kg 2.36 (0.70-7.96), 0
OR indicates odds ratio; CI, confidence interval; WBC, white blood cells.recovery was 27 days and 20 days after transplantation
of BM and PBPC grafts, respectively. Corresponding
day 60 probabilities of platelet recovery were 67%
(95% CI 57%-76%) and 79% (95% CI 73%-85%).
In multivariate analysis, platelet recovery after BM
transplantation was not associated with white blood
cell count, myeloid, or lymphoid subsets or activated
lymphoid cells. Platelet recovery was more likely
with PBPC grafts containing .8 107/kg CD31
CD81 cells (odds ratio [OR] 2.80, 95% CI 1.25-
6.28, P5 .01) (Table 2).
Acute GVHD and cGVHD
The day 100 probabilities of grade II-IV aGVHD
were 43% and 54% after transplantation of BM and
PBPC, respectively. The 1-year probabilities of
cGVHD were 31% and 44% after transplantation of
BM and PBPC, respectively. In multivariate analysis,
aGVHD and cGVHD were not associated with white
blood cell count, myeloid, or lymphoid subsets, or ac-
tivated lymphoid cells (Table 3).CI), P-Value Platelet Recovery OR (95% CI), P-Value
3 1.98 (0.82-4.76), 0.13
0.75 (0.32-1.78), 0.51
1.34 (0.57-3.17), 0.51
0.75 (0.32-1.78), 0.51
0.47 (0.18-1.21), 0.12
0.80 (0.31-2.03), 0.63
1.70 (0.66-4.35), 0.27
1.55 (0.62-3.88), 0.35
0.82 (0.34-1.97), 0.66
5% CI), P-Value Platelet Recovery OR (95% CI), P-Value
.79 2.04 (0.90-4.60), 0.09
.79 2.32 (1.05-5.16), 0.04
.40 1.00 (0.46-2.17), 0.99
.40 1.92 (0.88-4.17), 0.10
.38 1.22 (0.56-2.66), 0.62
.17 2.80 (1.25-6.28), 0.01
0.02 2.29 (1.02-5.13), 0.04
0.06 1.18 (0.55-2.55), 0.67
.17 1.69 (0.78-3.67), 0.19
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Forty-six of 94 (49%) recipients of BM and 67 of
181 (37%) recipients of PBPC transplants were alive
at the last contact. Inmultivariate analysis of BM trans-
plants, overall mortality was not associated with white
blood cell count, myeloid, or lymphoid subsets, or ac-
tivated lymphoid cells (Table 4). In contrast, higher
CD341 cell dose (.5 106/kg) was associated with
lower risks of mortality (relative risk [RR] 0.58, 95%
CI 0.39-0.84, P \ .01) after PBPC transplants. No
other myeloid or lymphoid subset or activated lym-
phoid cells were associated with OS (Table 4). The
1-year probabilities of OS were 59% and 34% when
PBPC grafts contained .5 106/kg and #5 106/
kg CD341 cells, respectively.DISCUSSION
The composition of a hematopoietic progenitor
cell graft is a major determinant of clinical outcome.
It has been seen in grafts from both related [17,18]
and unrelated [19,20] donors that when grafts are an-
alyzed for cell dose by various phenotypic markers
(eg, CD34, DR, CD3) associations are seen with clin-
ical outcomes such as survival, rate, and type of he-
matologic recovery, or GVHD. The BM or PBPC
source for the graft has a profound effect on cellular
composition and the cell dose, because mobilized PBTable 3. Multivariate Analysis of Grade II-IV aGVHD and cGVHD
Bone Marrow Acute GVHD II-IV RR (95%
WBC
>2.34 versus #2.34, 108/kg 0.67 (0.33-1.12), 0.
CD34+
>3.62 versus #3.62, 106/kg 0.79 (0.43-1.44), 0.
CD34+ CD382
>9.44 versus #9.44, 104/kg 0.85 (0.47-1.55), 0.
CD3+
>2.54 versus #2.54, 107/kg 0.57 (0.31-1.06), 0.
CD3+ CD4+
>1.33 versus #1.33, 107/kg 0.93 (0.49-1.76), 0.
CD3+ CD8+
>1.09 versus #1.09, 107/kg 0.80 (0.42-1.53), 0.
CD3+ CD25+
>3.05 versus #3.05, 106/kg 0.94 (0.50-1.91), 0.
CD3+ CD69+
>3.38 versus #3.38, 106/kg 0.71 (0.37-1.36), 0.
CD3+ HLA-DR+
>3.92 versus #3.92, 106/kg 0.88 (0.47-1.62), 0.
Peripheral blood progenitor cells Acute GVHD 2-4 R
WBC >7.23 versus #7.23, 108/kg 1.19 (0.79-
CD34+ > 5.41 versus #5.41, 106/kg 1.17 (0.78-
CD34+ CD382 >1.54 versus #1.54, 105/kg 1.63 (1.08-
CD3+ >2.37 versus #2.37, 108/kg 1.13 (0.75-
CD3+ CD4+ >1.45 versus #1.45, 108/kg 1.19 (0.79-
CD3+ CD8+ >8.37 versus #8.37, 107/kg 1.08 (0.72-
CD3+ CD25+ >2.46 versus #2.46, 107/kg 1.20 (0.80-
CD3+ CD69+ >3.55 versus #3.55, 106/kg 1.05 (0.70-
CD3+ HLA-DR+ >2.18 versus #2.18, 107/kg 0.79 (0.53-
RR indicates relative risk; GVHD, graft-versus-host disease; CI, confidence intcontains a larger number but lesser percentage of
primitive myeloid cells and much greater numbers
and higher percentage of mature T cells than BM.
Not surprisingly, this reciprocal relationship of cell
types and doses between BM and PBPC grafts can
lead to vastly different clinical outcomes [21-24].
However, several comparative analyses have been
published, including the Blood and Marrow Trans-
plant Clinical Trials Network (BMT CTN) protocol
0201, which recently completed enrollment of 550
patients randomized to unrelated donor BM or mobi-
lized blood grafts. In earlier trials, prospective testing
has not been done using a single reference laboratory
to determine the relationship between graft composi-
tion and transplantation outcome.
Laboratory processing of BM or PBPC also has
a major effect on the cellular composition of the final
graft. The common laboratory procedures of plasma
depletion and RBC reduction are done to reduce risks
of transfusion reactions in the recipient with minimal
stem cell loss. The expected effect of processing on
graft composition is necessary to plan the optimal vol-
ume of BM cells to be collected or number of apheresis
procedures.
As expected, in this study substantial variability was
seen in the cellular graft composition of BM and PBPC
grafts both before and after common manipulations of
RBC removal or plasma depletion. In BM grafts the
cellular composition was not associated withCI), P-Value Chronic GVHD RR (95% CI), P-Value
11 1.05 (0.51-2.14), 0.90
43 0.94 (0.47-1.90), 0.87
60 1.24 (0.61-2.53), 0.55
07 0.95 (0.47-1.91), 0.88
83 0.90 (0.43-1.91), 0.79
49 1.05 (0.50-2.21), 0.90
85 0.76 (0.36-1.61), 0.47
30 0.81 (0.37-1.79), 0.61
67 0.58 (0.28-1.19), 0.14
R (95% CI), P-Value Chronic GVHD RR (95% CI), P-Value
1.78), 0.41 1.07 (0.69-1.66), 0.77
1.76), 0.44 0.79 (0.51-1.22), 0.29
2.46), 0.02 0.98 (0.63-1.52), 0.93
1.69), 0.57 1.21 (0.77-1.89), 0.41
1.78), 0.41 1.41 (0.90-2.21), 0.13
1.62), 0.72 1.48 (0.95-2.32), 0.09
1.82), 0.38 1.42 (0.91-2.23), 0.13
1.57), 0.83 1.10 (0.71-1.71), 0.68
1.18), 0.25 0.89 (0.57-1.37), 0.58
erval.
Table 4. Multivariate Analysis of Overall Mortality
Bone Marrow Peripheral Blood Progenitor Cells
Graft Composition RR (95% CI), P-Value Graft Composition RR (95% CI), P-Value
WBC WBC
>2.34 versus #2.34, 108 /kg 0.64 (0.36-1.16), .14 >7.23 versus #7.23, 108 /kg 0.68 (0.46-0.98), .04
CD34+ CD34+
>3.62 versus #3.62, 106 /kg 0.71 (0.40-1.27), .25 > 5.41 versus #5.41, 106 /kg 0.58 (0.39-0.84), <.01
CD34+ CD382 CD34+ CD382
>9.44 versus #9.44, 104 /kg 0.67 (0.37-1.21), .18 >1.54 versus #1.54, 105 /kg 1.04 (0.71-1.51), .85
CD3+ CD3+
>2.54 versus #2.54, 107 /kg 0.72 (0.41-1.29), .27 >2.37 versus #2.37, 108 /kg 0.75 (0.52-1.09), .13
CD3+ CD4+ CD3+ CD4+
>1.33 versus #1.33, 107 /kg 0.98 (0.52-1.86), .96 >1.45 versus #1.45, 108 /kg 0.80 (0.55-1.16), .25
CD3+ CD8+ CD3+ CD8+
>1.09 versus #1.09, 107 /kg 0.86 (0.45-1.65), .66 >8.37 versus #8.37, 107 /kg 0.66 (0.45-0.96), .03
CD3+ CD25+ CD3+ CD25+
>3.05 versus #3.05, 106 /kg 0.83 (0.41-1.68), .60 >2.46 versus #2.46, 107 /kg 0.89 (0.62-1.30), .55
CD3+ CD69+ CD3+ CD69+
>3.38 versus #3.38, 106 /kg 0.55 (0.29-1.04), .07 >3.55 versus #3.55, 106 /kg 0.77 (0.53-1.12), .18
CD3+ HLA-DR+ CD3+ HLA-DR+
>3.92 versus #3.92, 106 /kg 0.83 (0.46-1.52), .55 >2.18 versus #2.18, 107 /kg 0.67 (0.46-0.98), .04
RR indicares relative risk; CI, confidence interval; WBC, white blood cells.
260 Biol Blood Marrow Transplant 16:253-262, 2010N. H. Collins et al.hematopoietic recovery, GVHD, or survival, whereas
in PBPC grafts, superior survival was seen when grafts
contained .5 106 CD341/kg, and superior platelet
recovery was seen when grafts contained .8 107
CD31 CD81/kg. However, neither survival nor
GVHD were altered by any other cellular subsets in
PBPC grafts.
In this report, a central reference laboratory was
used to ensure that data on the composition of the
grafts examined were consistent and reliable. Impor-
tantly, the study demonstrated that the data integrity
is dependent on the products (samples analyzed) being
an accurate representation of the transplanted graft
and that the sample analyzed is relatively unaffected
by storage or transportation prior to analysis. Im-
proper storage and transport of products could differ-
entially affect the viability of myeloid and lymphoid
elements, leading tomisleading interpretations.Multi-
center studies using central reference laboratories
must utilize uniform shipping protocols that ensure
graft viability and integrity including temperature con-
trol and prompt delivery to the analyzing laboratory.
The clinical decision determining the optimal cell
source and total cell number in the graft is dependent
on the choice of cell source, the expected yield, how
the graft is processed, and the reliability of phenotyp-
ing data obtained from samples. Determining the op-
timal graft composition of BM and PBPC could
better serve the recipients and minimize demands on
volunteer unrelated donors.ACKNOWLEDGMENTS
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